JUNS draws $3.6M from Yorkville equity line as share count reaches 56.5 million
A July 28 Form 8-K puts JUNS in focus: Jupiter Neurosciences, Inc. issued 11,470,000 shares of common stock to YA II PN, Ltd. (Yorkville) between May 14 and July 24, 2026, pulling approximately $3.6 million in gross proceeds through its standby equity purchase agreement. As of the filing date, the company's total shares outstanding stand at 56,520,143.
A July 28 Form 8-K puts JUNS in focus: Jupiter Neurosciences, Inc. issued 11,470,000 shares of common stock to YA II PN, Ltd. (Yorkville) between May 14 and July 24, 2026, pulling approximately $3.6 million in gross proceeds through its standby equity purchase agreement. As of the filing date, the company's total shares outstanding stand at 56,520,143.
The standby facility and its terms
Jupiter Neurosciences entered the Standby Equity Purchase Agreement with Yorkville, a Cayman Islands exempt limited partnership, on October 24, 2025. The facility carries a total capacity of up to $20 million in common stock sales, par value $0.0001 per share. Jupiter holds the right, but no obligation, to draw on the line subject to conditions set out in the agreement, giving management control over the timing and size of each advance.
Each advance is priced at 97% of the lowest daily volume-weighted average price of JUNS on the Nasdaq Capital Market during the three consecutive trading days starting on the date the advance notice is delivered. The structure means Yorkville absorbs shares at a discount to the market print. The transaction relies on the exemption from registration under Section 4(a)(2) of the Securities Act of 1933 and Rule 506(b) of Regulation D, with Yorkville representing itself as an accredited investor acquiring shares for investment rather than distribution.
What the print means for the setup
Advance notices delivered between May 14 and July 24, 2026 produced 11,470,000 shares and approximately $3.6 million in gross proceeds, with each tranche priced at the 97% VWAP-discount formula. Because these shares were issued in an exempt transaction rather than a registered offering, they carry restrictions that distinguish them from freely tradeable registered stock. The total shares outstanding, confirmed at 56,520,143 as of July 28, give investors a current dilution baseline against the remaining capacity still available under the $20 million facility ceiling.
Jupiter Neurosciences is incorporated in Delaware and classified as an emerging growth company listed on the Nasdaq Capital Market. The company operates from 11621 Kew Gardens Avenue, Suite 210, in Palm Beach Gardens, Florida. Chief Executive Officer Christer Rosén signed the filing.
What to watch
The next confirmable datapoint for JUNS holders is any new advance notice delivered under the SEPA, which would trigger a fresh three-day pricing window and a corresponding share issuance at the 97% VWAP discount. The SEPA was first publicly disclosed in the company's Form 8-K filed October 27, 2025, then amended through a Form 8-K/A on November 20, 2025. Both filings are incorporated by reference into the July 28 report.
Related reading
Filed by the newsroom of MarketPR on July 29, 2026. Source: sec.gov. Indicative figures are not investment advice.